Inhibition of GSK3β rescues hippocampal development and learning in a mouse model of CDKL5 disorder

Neurobiology of Disease

Volumn 82, Issue , 2015, Pages 298-310

  Fuchs, Claudia ^a   Rimondini, Roberto ^b   Viggiano, Rocchina ^a   Trazzi, Stefania ^a   De Franceschi, Marianna ^a   Bartesaghi, Renata ^a   Ciani, Elisabetta ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

CDKL5 disorder; Encephalopathy; GSK3 inhibitor; Pharmacotherapy; Rescue of hippocampal developmental

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; GLYCOGEN SYNTHASE KINASE 3BETA; CDKL5 PROTEIN, MOUSE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; NEUROPROTECTIVE AGENT; NOOTROPIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BRAIN DEVELOPMENT; BRAIN NERVE CELL; CDKL5 GENE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYCLIN DEPENDENT KINASE LIKE 5 DISORDER; DENDRITE; DENTATE GYRUS; DRUG EFFECT; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE; GRANULE CELL; HIPPOCAMPUS; HISTOLOGY; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; LEARNING; MALE; MEMORY; MORPHOLOGY; MORRIS WATER MAZE TEST; MOUSE; MUTANT; NONHUMAN; PASSIVE AVOIDANCE; PHENOTYPE; PHYSICAL DEVELOPMENT; POSTNATAL DEVELOPMENT; PRIORITY JOURNAL; STEREOLOGY; SYNAPSE; WESTERN BLOTTING; X CHROMOSOME LINKED DISORDER; ANIMAL; ANTAGONISTS AND INHIBITORS; DEFICIENCY; DISEASE MODEL; DRUG EFFECTS; ENZYMOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; LEARNING DISORDERS; MAZE TEST; METABOLISM; NERVE CELL; NERVOUS SYSTEM DEVELOPMENT; NEURAL STEM CELL; PATHOLOGY; PHYSIOLOGY; SPATIAL MEMORY;

ANIMALS; APOPTOSIS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; INDOLES; LEARNING DISORDERS; MALE; MALEIMIDES; MAZE LEARNING; MICE, KNOCKOUT; NEURAL STEM CELLS; NEUROGENESIS; NEURONS; NEUROPROTECTIVE AGENTS; NOOTROPIC AGENTS; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; SPATIAL MEMORY;

EID: 84936993294     PISSN: 09699961     EISSN: 1095953X     Source Type: Journal    
DOI: 10.1016/j.nbd.2015.06.018     Document Type: Article

References (33)

1. Amaral D.G., Witter M.P. Hippocampal formation. The Rat Nervous System 1995, 443-492. Academic Press. G. Paxinos (Ed.).
2. Amendola E., Zhan Y., Mattucci C., Castroflorio E., Calcagno E., Fuchs C., Lonetti G., Silingardi D., Vyssotski A.L., Farley D., Ciani E., Pizzorusso T., Giustetto M., Gross C.T. Mapping pathological phenotypes in a mouse model of CDKL5 disorder. PLoS One 2014, 9:e91613.
3. Bain J., Plater L., Elliott M., Shpiro N., Hastie C.J., McLauchlan H., Klevernic I., Arthur J.S., Alessi D.R., Cohen P. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 2007, 408:297-315.
4. Belichenko P.V., Oldfors A., Hagberg B., Dahlstrom A. Rett syndrome: 3-D confocal microscopy of cortical pyramidal dendrites and afferents. Neuroreport 1994, 5:1509-1513.
5. Bianchi P., Ciani E., Guidi S., Trazzi S., Felice D., Grossi G., Fernandez M., Giuliani A., Calza L., Bartesaghi R. Early pharmacotherapy restores neurogenesis and cognitive performance in the Ts65Dn mouse model for Down syndrome. J. Neurosci. 2010, 30:8769-8779.
6. Chapleau C.A., Calfa G.D., Lane M.C., Albertson A.J., Larimore J.L., Kudo S., Armstrong D.L., Percy A.K., Pozzo-Miller L. Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations. Neurobiol. Dis. 2009, 35:219-233.
7. Chen Q., Zhu Y.C., Yu J., Miao S., Zheng J., Xu L., Zhou Y., Li D., Zhang C., Tao J., Xiong Z.Q. CDKL5, a protein associated with Rett syndrome, regulates neuronal morphogenesis via Rac1 signaling. J. Neurosci. 2010, 30:12777-12786.
8. Cline G.W., Johnson K., Regittnig W., Perret P., Tozzo E., Xiao L., Damico C., Shulman G.I. Effects of a novel glycogen synthase kinase-3 inhibitor on insulin-stimulated glucose metabolism in Zucker diabetic fatty (fa/fa) rats. Diabetes 2002, 51:2903-2910.
9. Cohen P., Goedert M. GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov. 2004, 3:479-487.
10. Contestabile A., Fila T., Ceccarelli C., Bonasoni P., Bonapace L., Santini D., Bartesaghi R., Ciani E. Cell cycle alteration and decreased cell proliferation in the hippocampal dentate gyrus and in the neocortical germinal matrix of fetuses with Down syndrome and in Ts65Dn mice. Hippocampus 2007, 17:665-678.
11. Couillard-Despres S., Winner B., Schaubeck S., Aigner R., Vroemen M., Weidner N., Bogdahn U., Winkler J., Kuhn H.G., Aigner L. Doublecortin expression levels in adult brain reflect neurogenesis. Eur. J. Neurosci. 2005, 21:1-14.
12. Cross D.A., Alessi D.R., Cohen P., Andjelkovich M., Hemmings B.A. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 1995, 378:785-789.
13. Fehr S., Wilson M., Downs J., Williams S., Murgia A., Sartori S., Vecchi M., Ho G., Polli R., Psoni S., Bao X., de Klerk N., Leonard H., Christodoulou J. The CDKL5 disorder is an independent clinical entity associated with early-onset encephalopathy. Eur. J. Hum. Genet. 2013, 21:266-273.
14. Fuchs C., Trazzi S., Roberta T., Viggiano R., De Franceschi M., A.E., Gross C.T., Calzà L., Bartesaghi R., Ciani E. Loss of Cdkl5 impairs survival and dendritic growth of newborn neurons by altering AKT/GSK-3beta signaling. Neurobiol. Dis. 2014, 10.1016/j.nbd.2014.06.006.
15. Gross E.R., Hsu A.K., Gross G.J. Delayed cardioprotection afforded by the glycogen synthase kinase 3 inhibitor SB-216763 occurs via a KATP- and MPTP-dependent mechanism at reperfusion. Am. J. Physiol. Heart Circ. Physiol. 2008, 294:H1497-H1500.
16. Guerrini R., Parrini E. Epilepsy in Rett syndrome, and CDKL5- and FOXG1-gene-related encephalopathies. Epilepsia 2012, 53:2067-2078.
17. Guidi S., Stagni F., Bianchi P., Ciani E., Ragazzi E., Trazzi S., Grossi G., Mangano C., Calza L., Bartesaghi R. Early pharmacotherapy with fluoxetine rescues dendritic pathology in the Ts65Dn mouse model of down syndrome. Brain Pathol. 2013, 23:129-143.
18. Guo W., Murthy A.C., Zhang L., Johnson E.B., Schaller E.G., Allan A.M., Zhao X. Inhibition of GSK3beta improves hippocampus-dependent learning and rescues neurogenesis in a mouse model of fragile X syndrome. Hum. Mol. Genet. 2012, 21:681-691.
19. Hur E.M., Zhou F.Q. GSK3 signalling in neural development. Nat. Rev. Neurosci. 2010, 11:539-551.
20. Kempermann G., Jessberger S., Steiner B., Kronenberg G. Milestones of neuronal development in the adult hippocampus. Trends Neurosci. 2004, 27:447-452.
21. Kondratiuk I., Devijver H., Lechat B., Van Leuven F., Kaczmarek L., Filipkowski R.K. Glycogen synthase kinase-3beta affects size of dentate gyrus and species-typical behavioral tasks in transgenic and knockout mice. Behav. Brain Res. 2013, 248:46-50.
22. Llorens-Martin M., Fuster-Matanzo A., Teixeira C.M., Jurado-Arjona J., Ulloa F., Defelipe J., Rabano A., Hernandez F., Soriano E., Avila J. GSK-3beta overexpression causes reversible alterations on postsynaptic densities and dendritic morphology of hippocampal granule neurons in vivo. Mol. Psychiatry 2013, 18:451-460.
23. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193:265-275.
24. Luo J. The role of GSK3beta in the development of the central nervous system. Front. Biol. 2012, 7:212-220.
25. Medina M., Castro A. Glycogen synthase kinase-3 (GSK-3) inhibitors reach the clinic. Curr. Opin. Drug Discov. Dev. 2008, 11:533-543.
26. Nowakowski R.S., Lewin S.B., Miller M.W. Bromodeoxyuridine immunohistochemical determination of the lengths of the cell cycle and the DNA-synthetic phase for an anatomically defined population. J. Neurocytol. 1989, 18:311-318.
27. Pons-Espinal M., Martinez de Lagran M., Dierssen M. Environmental enrichment rescues DYRK1A activity and hippocampal adult neurogenesis in TgDyrk1A. Neurobiol. Dis. 2013, 60:18-31.
28. Ricciardi S., Ungaro F., Hambrock M., Rademacher N., Stefanelli G., Brambilla D., Sessa A., Magagnotti C., Bachi A., Giarda E., Verpelli C., Kilstrup-Nielsen C., Sala C., Kalscheuer V.M., Broccoli V. CDKL5 ensures excitatory synapse stability by reinforcing NGL-1-PSD95 interaction in the postsynaptic compartment and is impaired in patient iPSC-derived neurons. Nat. Cell Biol. 2012, 14:911-923.
29. Rusconi L., Salvatoni L., Giudici L., Bertani I., Kilstrup-Nielsen C., Broccoli V., Landsberger N. CDKL5 expression is modulated during neuronal development and its subcellular distribution is tightly regulated by the C-terminal tail. J. Biol. Chem. 2008, 283:30101-30111.
30. Sutherland C. What Are the bona fide GSK3 substrates?. Int. J. Alzheimers Dis. 2011, 2011:505607.
31. Wada A. Lithium and neuropsychiatric therapeutics: neuroplasticity via glycogen synthase kinase-3beta, beta-catenin, and neurotrophin cascades. J. Pharmacol. Sci. 2009, 110:14-28.
32. Wang I.T., Allen M., Goffin D., Zhu X., Fairless A.H., Brodkin E.S., Siegel S.J., Marsh E.D., Blendy J.A., Zhou Z. Loss of CDKL5 disrupts kinome profile and event-related potentials leading to autistic-like phenotypes in mice. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:21516-21521.
33. Zhu Y.C., Li D., Wang L., Lu B., Zheng J., Zhao S.L., Zeng R., Xiong Z.Q. Palmitoylation-dependent CDKL5-PSD-95 interaction regulates synaptic targeting of CDKL5 and dendritic spine development. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:9118-9123.